118 related articles for article (PubMed ID: 15930304)
21. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
22. Guggulsterone-induced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase.
Singh SV; Choi S; Zeng Y; Hahm ER; Xiao D
Cancer Res; 2007 Aug; 67(15):7439-49. PubMed ID: 17671214
[TBL] [Abstract][Full Text] [Related]
23. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
24. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
25. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
26. Penta-O-galloyl-beta-D-glucose suppresses prostate cancer bone metastasis by transcriptionally repressing EGF-induced MMP-9 expression.
Kuo PT; Lin TP; Liu LC; Huang CH; Lin JK; Kao JY; Way TD
J Agric Food Chem; 2009 Apr; 57(8):3331-9. PubMed ID: 19320436
[TBL] [Abstract][Full Text] [Related]
27. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation.
Kukreja P; Abdel-Mageed AB; Mondal D; Liu K; Agrawal KC
Cancer Res; 2005 Nov; 65(21):9891-8. PubMed ID: 16267013
[TBL] [Abstract][Full Text] [Related]
28. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
29. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
30. Proteasome mediated degradation of Id-1 is associated with TNFalpha-induced apoptosis in prostate cancer cells.
Ling MT; Kwok WK; Fung MK; Xianghong W; Wong YC
Carcinogenesis; 2006 Feb; 27(2):205-15. PubMed ID: 16123120
[TBL] [Abstract][Full Text] [Related]
31. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
32. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.
Wang H; McKnight NC; Zhang T; Lu ML; Balk SP; Yuan X
Cancer Res; 2007 Jan; 67(2):528-36. PubMed ID: 17234760
[TBL] [Abstract][Full Text] [Related]
33. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
34. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
35. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
[TBL] [Abstract][Full Text] [Related]
36. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.
Araki S; Omori Y; Lyn D; Singh RK; Meinbach DM; Sandman Y; Lokeshwar VB; Lokeshwar BL
Cancer Res; 2007 Jul; 67(14):6854-62. PubMed ID: 17638896
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.
van der Poel HG
Eur Urol; 2005 Dec; 48(6):1051-8. PubMed ID: 16257107
[TBL] [Abstract][Full Text] [Related]
39. Androgen-mediated resistance to apoptosis.
Coffey RN; Watson RW; O'Neill AJ; Mc Eleny K; Fitzpatrick JM
Prostate; 2002 Dec; 53(4):300-9. PubMed ID: 12430141
[TBL] [Abstract][Full Text] [Related]
40. Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression.
Lee JW; Kim GY; Kim JH
Biochem Biophys Res Commun; 2012 Apr; 420(2):428-33. PubMed ID: 22426480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
